Reading the performance literature honestly
The strongest signal in the athletic performance research literature is that measurable, replicable performance gains come from training programming, sleep quality, calorie/protein sufficiency, and progressive overload. Peptides referenced in performance contexts are typically studied for narrow mechanistic questions in preclinical models — not for producing headline performance outcomes in humans.
Categories referenced in the literature
Peptide categories that appear in performance-related research include: growth-hormone secretagogues (e.g., GHRPs, GHRHs), tissue-repair-signaling peptides (e.g., BPC-157, TB-500 fragments), and metabolic signaling peptides (e.g., MOTS-c). Each category has a distinct research base — treating them as interchangeable is a common evaluation mistake.
How to evaluate a performance claim
A reliable evaluation checklist from the peer-reviewed literature: (1) Is the source a primary study or a summary? (2) Is the study preclinical (animal/in vitro) or human clinical? (3) What was the sample size and control? (4) Is the claimed effect replicated across independent labs? (5) Does the marketing extrapolate mechanism to outcome without evidence?
Regulatory and competition context
The World Anti-Doping Agency (WADA) publishes a Prohibited List that includes multiple peptide categories. Athletes in any tested sport must independently review that list against any compound they encounter in research reading. FDA approval for consumer use is absent for the vast majority of peptides discussed in performance contexts.